Search in:

Cancer Investigation Volume 30, 2012 - Issue 10

Submit an article Journal homepage

Open access

1,160

Views

CrossRef citations to date

Altmetric

ORIGINAL ARTICLE

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

Sofie WilgenhofDepartments of Medical Oncology and Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium

Stephanie Du FourDepartments of Medical Oncology and Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium

Hendrik EveraertDepartments of Medical Oncology and Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium

Bart NeynsDepartments of Medical Oncology and Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, BelgiumCorrespondence[email protected]

Pages 712-720 | Published online: 08 Oct 2012

Cite this article
https://doi.org/10.3109/07357907.2012.727934

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (10)

Robin Kate Kelley, Bruno Sangro, William Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shukui Qin, David W.-M. Tai, Ho Yeong Lim, Thomas Yau, Wei-Peng Yong, Ann-Lii Cheng, Antonio Gasbarrini, Silvia Damian, Jordi Bruix, Mitesh Borad, Johanna Bendell, Tae-You Kim, Nathan Standifer, Philip He, Mallory Makowsky, Alejandra Negro, Masatoshi Kudo & Ghassan K. Abou-Alfa. (2021) Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology 39:27, pages 2991-3001.
Crossref

Patricia M. LoRusso, Kurt Schalper & Jeffrey Sosman. (2020) Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell & Melanoma Research 33:3, pages 390-402.
Crossref

Wouter Ouwerkerk, Mirjam van den Berg, Sanne van der Niet, Jacqueline Limpens & Rosalie M. Luiten. (2019) Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Research 29:5, pages 453-464.
Crossref

Hana Studentova, Hana Kalabova, Pavel Koranda, Karin Chytilova, Ladislava Kucerova, Bohuslav Melichar & David Vrana. (2018) Immunotherapy in mucosal melanoma: a case report and review of the literature. Oncotarget 9:25, pages 17971-17977.
Crossref

Rebecca N. Jerome, Terri L. Edwards, Haley C. Boswell, Gordon R. Bernard, Paul A. Harris & Jill M. Pulley. (2016) Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients. Academic Medicine 91:3, pages 305-309.
Crossref

Akihiko Shimomura, Yutaka Fujiwara, Shunsuke Kondo, Makoto Kodaira, Satoru Iwasa, Shigehisa Kitano, Yuko Tanabe, Kenji Tamura & Noboru Yamamoto. (2016) Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy 8:1, pages 9-15.
Crossref

Christos Sachpekidis, Lionel Larribere, Leyun Pan, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss & Jessica C. Hassel. (2014) Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. European Journal of Nuclear Medicine and Molecular Imaging 42:3, pages 386-396.
Crossref

Lidia Robert, Jennifer Tsoi, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Thinle Chodon, Stephen Mok, Rong Rong Huang, Alistair J. Cochran, Begoña Comin-Anduix, Richard C. Koya, Thomas G. Graeber, Harlan Robins & Antoni Ribas. (2014) CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. Clinical Cancer Research 20:9, pages 2424-2432.
Crossref

Anna Maria Di Giacomo, Luana Calabrò, Riccardo Danielli, Ester Fonsatti, Erica Bertocci, Isabella Pesce, Carolina Fazio, Ornella Cutaia, Diana Giannarelli, Clelia Miracco, Maurizio Biagioli, Maresa Altomonte & Michele Maio. (2013) Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunology, Immunotherapy 62:6, pages 1021-1028.
Crossref

. (2013) Ipilimumab. Reactions Weekly 1445:1, pages 26-26.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

Articles from other publishers (10)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

Citations (10)

Articles from other publishers (10)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date